Lixte Biotechnology Holdings Stock Profit Margin
LIXT Stock | USD 1.99 0.08 4.19% |
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Last Reported | Projected for Next Year | ||
Net Loss | (12.83) | (13.48) |
Lixte | Profit Margin |
Lixte Biotechnology Holdings Company Profit Margin Analysis
Lixte Biotechnology's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Lixte Biotechnology Profit Margin | -13.48 |
Most of Lixte Biotechnology's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lixte Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Profit Margin. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
All Next | Launch Module |
Lixte Fundamentals
Return On Equity | -1.63 | ||||
Return On Asset | -0.87 | ||||
Current Valuation | 6.59 M | ||||
Shares Outstanding | 2.25 M | ||||
Shares Owned By Insiders | 20.40 % | ||||
Shares Owned By Institutions | 9.64 % | ||||
Number Of Shares Shorted | 136.43 K | ||||
Price To Earning | (2.96) X | ||||
Price To Book | 12.00 X | ||||
EBITDA | 3.21 K | ||||
Net Income | (5.09 M) | ||||
Cash And Equivalents | 7.74 M | ||||
Cash Per Share | 0.47 X | ||||
Total Debt | 313.86 K | ||||
Debt To Equity | 0.16 % | ||||
Current Ratio | 15.10 X | ||||
Book Value Per Share | 0.22 X | ||||
Cash Flow From Operations | (4.29 M) | ||||
Short Ratio | 0.31 X | ||||
Earnings Per Share | (1.73) X | ||||
Beta | -0.17 | ||||
Market Capitalization | 4.72 M | ||||
Total Asset | 4.31 M | ||||
Retained Earnings | (48.48 M) | ||||
Working Capital | 3.99 M | ||||
Current Asset | 1.38 M | ||||
Current Liabilities | 140 K | ||||
Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.